I. It is generally considered that the natural (3R,4R) Delta1- tetrahydrocannabinol (Delta1-THC) is only about 13-20 times more active than the synthetic (3S,4S) enantiomer. On the basis of preliminary work we consider that the stereospecificity of THC activity is, in actuality, absolute. We plan to prepare stereochemically pure enantiomers and test them in the mouse ring test and by drug discrimination techniques. II. We plan to prepare two new types of cannabinoid probes (labelled with tritium on the methyl group of cyclohexene ring and on one of the methyl groups of the pyran ring). We shall use these probes for the identification of possible new subgroups of the cannabinoid receptor. III. Little is known on the antiemetic SAR of cannabinoids. We plan to test for antiemetic activity in pigeons various natural and synthetic cannabinoids in order to establish SAR rules. On the basis of preliminary work we expect to be able to show that separation can be achieved between cannabimimetic and antiemetic activity. IV. Work by our group and that of S. Burstein has shown that separation between cannabimimetic and analgetic activity is possible. We plan to prepare compounds, mainly of two types (cannabinoid- 7-oic acids and monoalkyl ethers of cannabidiol type of compounds) for which preliminary indications exists for separation of activity. V. We have shown that (+)-7-OH-Delta6-THC dimethylhepty homolog (HU-211) blocks respiratory depression by morphine. We plan to expand our research in this area and to look for similar blocking of opiate activity in analgesia and gastrointestinal activity.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA006481-02
Application #
3213092
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1990-04-01
Project End
1993-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
2
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Hebrew University of Jerusalem
Department
Type
DUNS #
600044978
City
Jerusalem
State
Country
Israel
Zip Code
91904
Fride, E; Mechoulam, R (1996) Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice. Brain Res Dev Brain Res 95:131-4
Fride, E; Mechoulam, R (1996) Developmental aspects of anandamide: ontogeny of response and prenatal exposure. Psychoneuroendocrinology 21:157-72
Bayewitch, M; Rhee, M H; Avidor-Reiss, T et al. (1996) (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902-5
Mechoulam, R; Shabat, S B; Hanus, L et al. (1996) Endogenous cannabinoid ligands. Adv Exp Med Biol 402:95-101
Bayewitch, M; Avidor-Reiss, T; Levy, R et al. (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375:143-7
Fride, E; Barg, J; Levy, R et al. (1995) Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 272:699-707
Jarbe, T U; Mechoulam, R; Zahalka, J (1994) Discriminative stimulus- and open-field effects of the enantiomers of 11-hydroxy-delta-8-tetrahydrocannabinol in pigeons and gerbils. Pharmacol Biochem Behav 47:113-9
Jarbe, T U; Hiltunen, A J; Mathis, D A et al. (1993) Discriminative stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons;a comparison. J Pharmacol Exp Ther 264:561-9
Vogel, Z; Barg, J; Levy, R et al. (1993) Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 61:352-5
Burstein, S H; Audette, C A; Breuer, A et al. (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 35:3135-41

Showing the most recent 10 out of 12 publications